What You Should Know:

– The average person with diabetes could spend between $3,300 and $4,600 a year on out-of-pocket costs, including prescription medications, provider visits, over-the-counter supplies, and lost wages, according to a recent GoodRx report.

– The report, The True Cost of Diabetes takes into account medications, visits with healthcare providers, and blood sugar level monitoring, as well as costs for emergency room visits, hospital stays, and chronic complications for those with uncontrolled diabetes. 

Beyond the Basics: Insulin, CGMs, and the Pricey Pantry

For those reliant on insulin, GLP-1 agonists, or SGLT2 inhibitors, costs skyrocket. Out-of-pocket medication expenses can jump from $90 for basic oral meds to $560 with these advanced therapies. Uninsured patients face a quadruple whammy, with costs exceeding $4,200 annually.

Continuous glucose monitors (CGMs), those invaluable blood sugar monitoring devices, add another layer of expense. Even with insurance, they can cost around $80 per year, not to mention insulin cooling cases and other essential supplies.

And let’s not forget the invisible cost of managing diabetes: the time. Self-testing, foot care, exercise, and meal planning – it all eats away at precious hours, adding another layer of burden to an already demanding condition.

Lost Wages and the Domino Effect: The Indirect Costs of Diabetes

Diabetes doesn’t just drain wallets; it can drain bank accounts. Absenteeism due to illness is high among diabetic patients, translating to lost wages and potential job loss. This domino effect can lead to lost insurance, further exacerbating the financial strain.

The Tip of the Iceberg: Complications as Cost Catalysts

The true financial storm hits when diabetes complications arise. Hyperglycemia, hypoglycemia, ulcers, and even heart attacks can send patients to the ER, rack up hospital bills, and necessitate home health services. The average out-of-pocket cost for these services? Nearly $590 per year.

And that’s just the tip of the iceberg. Chronic complications like heart disease and kidney disease add another layer of expense, with medication and preventive care adding to the financial burden. Each additional chronic condition bumps up out-of-pocket costs by an average of $470 annually.

A Call to Action: Breaking the Financial Chains of Diabetes

The staggering costs of diabetes paint a grim picture, but it’s not a hopeless one. Early diagnosis, proactive management, and access to affordable medications and healthcare can help mitigate the financial strain. Policy changes, insurance reforms, and increased access to preventive care can also play a critical role in alleviating the financial burden for millions of Americans living with diabetes.

What You Should Know:

– In a move aimed at alleviating Arizona’s critical shortage of healthcare providers, Spectrum Healthcare, one of the state’s largest non-profit healthcare providers, has joined forces with NextGen Healthcare, a provider of cloud-based technology solutions.

– This strategic partnership marks a significant step towards improving access to integrated mind-body care for Arizonans, particularly in underserved communities.

A Growing Need for Whole-Person Care

Arizona faces a stark reality: 82 areas in the state lack adequate medical resources, and over 2.8 million residents live in communities struggling with a dearth of mental health professionals. Spectrum Healthcare, dedicated to serving these very communities for nearly six decades, understands the urgency of the situation.

“We are committed to providing accessible, whole-person care to all Arizonans,” says April Rhodes, CEO of Spectrum Healthcare. “Partnering with NextGen Healthcare allows us to leverage innovative technology solutions to elevate our care delivery and address the critical shortage of healthcare providers.”

Technology as the Bridge

NextGen Healthcare’s suite of cloud-based solutions, including the NextGen® Enterprise electronic health record (EHR), practice management (PM), and Population Health Solutions, will equip Spectrum Healthcare with powerful tools to streamline operations, improve interoperability, and optimize clinical and financial performance. This, in turn, translates into better resource utilization and the potential to reach more patients, particularly in underserved areas.

“Spectrum Healthcare’s dedication to serving their communities aligns perfectly with our mission to empower healthcare providers through innovative technology,” says Srinivas (Sri) Velamoor, President and Chief Operating Officer of NextGen Healthcare. “Together, we are confident in making a lasting impact throughout Arizona by creating greater access to care.”

Beyond Technology: A Holistic Approach

Spectrum Healthcare’s commitment to whole-person care extends beyond technology. In addition to its seven brick-and-mortar locations across Arizona, the organization offers telehealth and in-home services, operates mobile crisis teams, and partners with local schools to provide on-campus student care. This comprehensive approach ensures that vulnerable populations have access to the full spectrum of healthcare services they need, regardless of their location or circumstances.

What You Should Know:

Graphium Health, a leader in anesthesia technology solutions, has acquired The ABG Anesthesia Data Group, LLC (ABG). This strategic acquisition signifies Graphium Health’s unwavering commitment to improving patient safety and practice efficiency through innovative data management tools.

Simplifying Quality Reporting, Enhancing Care:

The ABG platform, renowned for its user-friendly interface, simplifies complex quality reporting requirements, particularly for the MIPS program. This empowers anesthesiologists, CRNAs, and CAAs to seamlessly integrate quality improvement initiatives into their daily workflow, ultimately enhancing patient care.

Beyond MIPS: A Holistic Approach to Anesthesia Excellence:

Graphium Health plans to integrate the ABG QCDR into its existing suite of solutions, creating a comprehensive platform that goes beyond MIPS compliance. This enhanced platform will offer:

• Quality Improvement (QI) and OPPE reports: Empowering providers to track progress and meet Joint Commission standards.
• Customizable QI bonus plans: Allowing practices to incentivize quality initiatives.
• MIPS-compliant patient experience surveys: Gathering valuable feedback to improve patient satisfaction.
• Industry-leading operational analytics: Providing real-time insights into surgical efficiency, throughput, and resource utilization.

Empowering Providers, Transforming Surgery:

By offering this comprehensive suite of tools and data-driven insights, Graphium Health empowers hospitals, anesthesiologists, and all surgical staff to:

• Track and measure quality metrics effectively: Ensuring consistent adherence to best practices.
• Improve the overall surgical patient experience: From streamlining workflows to fostering patient satisfaction.
• Navigate evolving regulatory landscapes with confidence: Adapting to changing CMS programs with ease.

A Shared Vision for Anesthesia Excellence:

“This acquisition is a testament to our unwavering commitment to advancing anesthesia quality and safety,” says Daniel Dura, CEO of Graphium Health. “By combining our expertise with ABG’s innovative platform, we create a powerful solution that empowers providers and elevates the entire surgical experience.”

What You Should Know:

– TruLite Health, a pioneer in health equity solutions, and Mayo Clinic, a global leader in medical care, today announced a groundbreaking collaboration to address disparities in medical outcomes and costs for diverse patient populations.

– This partnership marks a significant step forward in the fight against clinical bias, a pervasive issue that disproportionately impacts the health of Black, Latinx, and other minority communities.

Quantifying the Impact of Bias

Clinical bias has a staggering financial and human cost. A TruLite study revealed that individuals with one of seven chronic illnesses who are Black or Latinx incur approximately $5,300 more in annual healthcare expenses compared to their White counterparts. Truity™ aims to tackle this disparity head-on by ensuring all patients receive equitable care regardless of their background.

Truity™: AI Championing Fairness in Healthcare

TruLite’s revolutionary software, Truity™, identifies and mitigates clinical bias within electronic health records (EHRs). The platform analyzes patient data and suggests personalized interventions for clinicians, care teams, and patients themselves. These interventions address social and behavioral factors that often contribute to unequal healthcare outcomes, particularly for Black and Latinx populations.

Mayo Clinic: A Powerhouse Partner

Mayo Clinic brings its vast expertise and resources to the table. Their physicians will provide valuable feedback on Truity™, helping refine the user experience and workflow to maximize its effectiveness in clinical settings. Additionally, Mayo Clinic has a financial interest in the technology, demonstrating its commitment to advancing health equity solutions.

This partnership goes beyond software:

• Virtual health equity coaching: TruLite offers virtual coaching programs to empower patients and advocate for their healthcare needs.
• Partnership with Morehouse School of Medicine: TruLite collaborates with Morehouse to address the specific healthcare challenges faced by Black communities.

“This collaboration with Mayo Clinic represents a critical milestone in the fight for health equity,” says Dr. Alan Roga, Founder and CEO of TruLite. “Mayo Clinic’s expertise and commitment to patient care, combined with TruLite’s innovative technology, will allow us to reach a wider audience and make a real difference in people’s lives.”

What You Should Know:

– Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.

– This strategic partnership combines Debiopharm’s deep pharmaceutical expertise with TNL’s revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.

Unlocking the Hidden Potential of a Promising Drug

The partnership focuses on unlocking the full potential of one of Debiopharm’s promising cancer drugs. By leveraging TNL’s AI-powered platform, the collaboration will explore:

• Expanding Indications: TNL’s platform will identify potential new applications for the drug, extending its reach and impact on cancer patients.
• Combination Therapy Optimization: Utilizing AI digital knockdowns, the team will identify synergistic combinations with other drugs in development, maximizing the therapeutic efficacy of Debiopharm’s cancer drug.
• Mechanism of Action Validation: TNL’s digital cell clones will provide a deeper understanding of the drug’s mechanism of action, ensuring targeted and effective treatment strategies.
• Comparative Analysis: Digital cell clones will enable side-by-side comparisons with existing cancer treatments, providing valuable insights for optimal drug selection and development.
• Biomarker Discovery: The partnership will focus on identifying predictive biomarkers that can guide patient selection and treatment personalization, ultimately improving patient outcomes.

“This partnership represents a significant leap forward in cancer drug development,” said Bertrand Ducrey, CEO of Debiopharm. “By combining our expertise with TNL’s innovative AI platform, we are confident in unlocking the full potential of this promising drug and bringing it to even more patients in need.”

What You Should Know:

– Innovaccer, a healthcare data platform, unveils Sara Scribe, an AI assistant poised to revolutionize healthcare documentation.

– Sara Scribe, also known as InScribe, transcends the limitations of standard dictation software. This innovative tool uses advanced AI to not only transcribe doctor-patient conversations in real-time but also analyze them and deliver actionable insights, streamlining workflows and freeing up valuable clinician time.

Beyond Transcription: Clinical Intelligence at Your Fingertips

Sara Scribe is more than just a transcriptionist; it’s a clinical advisor. It analyzes conversations and leverages EHR and claims data to identify:

– Quality gaps: Potential areas for improvement in patient care.

– Coding gaps: Opportunities to optimize reimbursement through accurate coding.

– Potential diagnoses: Early flags for possible health conditions, enabling proactive care.

This real-time guidance empowers clinicians to make informed decisions, optimize care delivery, and improve patient outcomes.

Two Modes to Fit Every Need

Innovaccer caters to both large and small healthcare providers with two distinct InScribe modalities:

Enterprise: Seamlessly integrated with Innovaccer’s existing Point-of-Care assistant, InNote, this version elevates user experience with ambient documentation and clinical insights drawn from comprehensive EHR and claims data.

Individual: Designed for independent practitioners and smaller groups, this standalone web-based tool boasts an intuitive mobile companion app. Users can sign up and begin using InScribe within minutes, making it accessible and convenient.

“InScribe isn’t just a transcription tool—it’s a game-changer in the AI assistant space. It not only documents the conversation but also nudges the provider with real-time clinical insights during a visit,” Abhinav Shashank, Cofounder and CEO, Innovaccer. “We understand burnout is at an all-time high. With InScribe, we aim to reduce the administrative and cognitive load of clinicians and redirect their time back to patients.”

What You Should Know:

– Impact Advisors, a leading healthcare management consulting firm, announced today the acquisition of First Quadrant Advisory, a renowned specialist in strategy and operations consulting for the healthcare payer market.

– This strategic acquisition strengthens Impact Advisors’ commitment to delivering comprehensive, value-driven solutions for both payer and provider organizations, and further propels its mission to improve the business and delivery of healthcare.

Enhanced Capabilities, Shared Values

The acquisition expands Impact Advisors’ offerings with First Quadrant’s expertise in product design, value-based care, digital health, and operational efficiency, providing comprehensive solutions across the healthcare value chain. Both firms share a commitment to client success and a people-centered culture, fostering seamless integration and collaboration. The seasoned teams bring a wealth of industry leadership and consulting experience, benefitting clients with diverse perspectives and proven solutions.

“We are thrilled to welcome First Quadrant Advisory into our fold. Their expertise in the payer market and shared values make them a perfect fit for our mission to improve healthcare delivery. Together, we will offer even more value-driven solutions to our clients,” said Sandeep Sabharwal, Managing Partner at Impact Advisors.

What You Should Know:

– XRHealth, the leading healthcare platform in Spatial Computing, announced today a $6M funding round led by Asabys Partners, with participation from NOVA Prime Fund and XRHealth’s existing investors.

– This milestone follows the successful merger with Amelia Virtual Care, solidifying XRHealth’s position as the largest extended reality (XR) platform encompassing mental, physical, and occupational health.

VR/AR Meets Patient Needs

XRHealth’s platform leverages virtual clinics, immersive VR/AR experiences, and advanced data analytics to empower healthcare providers. Patients receive treatment from the comfort of their homes for a wide range of conditions, including acute and chronic pain, post-stroke rehabilitation, fibromyalgia, anxiety, stress, dementia, and more.

Growth Plans

The funding will support the integration of XRHealth and Amelia Virtual Care, creating a powerhouse platform for immersive healthcare experiences. In addition, the funding will fuel the development of an AI-powered clinician, alleviating the burden on human healthcare professionals and expanding access to care for millions globally.

“This funding empowers us to accelerate the growth of our platform, democratizing healthcare through immersive VR/AR technology and AI. We’re excited to pioneer an AI clinician in Spatial Computing, opening doors to a future where everyone receives quality care, regardless of location,” said Eran Orr, CEO of XRHealth.

What You Should Know:

– Care Continuity, a leading provider of data-driven patient navigation solutions, has secured $10M in Series A-3 funding, fueling its mission to streamline healthcare journeys and optimize network utilization. The investment, co-led by Empactful Capital & Viewside Capital Partners with participation from Flat Creek Capital and Loop 289 Limited Partners, empowers Care Continuity to further enhance its platform and reach, impacting both providers and patients across the healthcare ecosystem.

– The funding will fuel the integration of AI capabilities to further personalize care journeys, improve outreach efficiency, and connect more patients with the right care at the right time.

Enhancing the Care Journey

• Patient-Centered Navigation: Care Continuity’s expertise lies in guiding patients through complex healthcare networks, ensuring they access the right care at the right time. This reduces patient leakage and strengthens network utilization.
• AI-Powered Solutions: The funding empowers Care Continuity to integrate advanced AI capabilities into its platform. This enhances patient reach, improves efficiency, and personalizes the navigation experience.
• Data-Driven Insights: Beyond patient navigation, Care Continuity offers sophisticated analytics and digital tools. These valuable resources help payers, ACOs, and healthcare providers engage their members and optimize network performance.

Expansion Plans

The company plans to invest in expanding its team, focusing on sales, marketing, technology, data science, and advisory services, propelling its growth trajectory. In addition, Care Continuity will utilize the investment to expand its platform features, offering even more comprehensive and targeted navigation solutions for various patient needs and healthcare settings.

This funding allows us to empower both providers and patients at a critical juncture. We’ll enhance our platform and leverage AI to connect more patients to the right care within their networks, driving efficiency and positive health outcomes,” said Brad Prugh, Care Continuity CEO.

What You Should Know:

– Healthcare industry leaders Ventra Health and ADVOCATE RCM announced a groundbreaking merger today, joining forces to become one of the nation’s largest and most advanced providers of end-to-end revenue cycle management (RCM) services.

– This strategic move expands Ventra’s reach beyond its core specialties in anesthesia, emergency medicine, and hospital medicine, while ADVOCATE RCM gains access to Ventra’s extensive resources and network.

Merger Impact

Ventra gains immediate access to ADVOCATE RCM’s expertise in radiology and other facility-based specialties, offering clients a comprehensive suite of RCM solutions. The combined organization boasts best-in-class technology and a shared commitment to continuous innovation, further streamlining RCM processes and optimizing financial performance for clients. Clients of both companies will benefit from the combined expertise of two industry leaders, ensuring exceptional service and consistent revenue results.

“Bringing ADVOCATE RCM’s talent and technology under our umbrella strengthens our commitment to exceptional RCM and solidifies our position as a trusted partner for healthcare providers nationwide,” said Steven Huddleston, Ventra CEO in a statement.

Financial details of the merger were not disclosed.

What You Should Know:

– Samsung Electronics is pushing the boundaries of preventive healthcare with the expansion of its Privileged Health Software Development Kit (SDK) program.

– This SDK expansion unlocks the Galaxy Watch’s cutting-edge sensor technology for developers, fostering partnerships that bring a wave of innovative health solutions to users.

Empowering Users with Personalized Health Insights

At the heart of this program lies user empowerment. By integrating Galaxy Watch data with diverse platforms, Samsung and its partners empower individuals to actively manage their health. From real-time vital sign monitoring to personalized sleep environments, the focus is on proactive well-being.

Remote Patient Monitoring: Bridging the Distance

The Galaxy Watch becomes a bridge between patients and their healthcare providers, enabling seamless remote monitoring. Partners like Biofourmis and Kencor Health leverage the watch’s biometric data to deliver personalized care and predict potential health issues, allowing for timely interventions and improved clinical management.

Heart Health and Beyond: AI-powered Insights for Everyone

Medical AI’s advanced ECG services, powered by the Galaxy Watch’s technology, provide real-time arrhythmia detection and proactive alerts for patients with heart conditions. Oova, an AI-powered women’s health platform, integrates menstrual cycle data with Galaxy Watch biometrics, offering personalized guidance and precise fertility predictions.

XR Therapy at Home: Immersive Wellness Within Reach

Samsung’s partnership with XRHealth brings extended reality (XR) therapy to the comfort of home. By monitoring heart rate during virtual exercise sessions, the Galaxy Watch acts as a real-time pacer, providing valuable feedback for personalized physical and mental health therapy. Healium’s bio-feedback platform utilizes Galaxy Watch data to create immersive visual experiences, helping users understand and manage stress levels through intuitive visual feedback.

Personalized Sleep: A Holistic Approach to Rest

Recognizing the importance of sleep for overall health, Samsung is expanding its sleep technology beyond the Galaxy Watch. Partnerships with smart mattress companies like 3Boon1 create personalized sleep environments that optimize temperature for uninterrupted rest. By combining Galaxy Watch data with the mattress’s AI algorithm, users can achieve optimal sleep conditions, tailored to their individual needs.

What You Should Know:

– Omada Health, a leading virtual-first healthcare provider, today announced a groundbreaking partnership with Amazon Health Services. This collaboration brings Omada’s comprehensive programs for diabetes prevention, diabetes management, and hypertension care to the forefront of Amazon’s new Health Condition Programs initiative.

– As the first virtual provider featured in this program, Omada will empower millions of individuals with Amazon accounts to discover and enroll in valuable health benefits offered by their employers or health plans, often at no extra cost.

Seamless Enrollment from Product Browsing to Program Access

Amazon customers browsing for diabetes prevention, diabetes, and hypertension products will now encounter a seamless path to explore their eligibility for Omada’s programs. A simple eligibility check on the Amazon Health webpage can lead individuals directly to Omada’s website for enrollment. This strategic placement within Amazon’s vast reach aims to significantly increase awareness and enrollment for Omada’s services, currently benefiting over 1,900 employers and health plans, impacting over 20 million lives.

Proven Results, Long-Term Impact

With over 12 years of experience, Omada boasts a remarkable track record. 88% of program participants report satisfaction, and the diabetes program demonstrates exceptional outcomes:

– 12-month A1C decrease of 2.0% for members with baseline A1C above 8%.

– 76% of members achieving Omada’s A1C reduction goals.

These findings showcase the program’s effectiveness in managing blood sugar levels and reducing A1C for long-term health benefits.

“Amazon wants to make it easier for people to get and stay healthy, and part of that is making it easier to discover the products, services, and professionals that can help them do that. Many aren’t aware of the healthcare benefits they are eligible for, that are typically no cost or subsidized by their employer or insurance plan,” says Aaron Martin, Vice President, Amazon. “When customers are shopping for health-related products on Amazon, we can surface these benefits to provide even more support in improving their health, at no additional cost.”

What You Should Know:

– In a groundbreaking collaboration, Aiforia, an AI company specializing in pathology solutions, and Mayo Clinic have announced the exclusive licensing of a revolutionary AI model that improves the prediction of colorectal cancer recurrence.

– The successful development and licensing of this AI model marks a significant milestone in the fight against colorectal cancer. As this technology becomes integrated into clinical practice, it has the potential to transform the landscape of cancer care, leading to improved patient outcomes, reduced treatment costs, and a more personalized approach to managing this prevalent disease.

AI Model

The AI model, meticulously trained on extensive datasets, analyzes digitized tissue samples to identify 15 key histological features. By combining this data with two additional clinical parameters, it generates a personalized colorectal cancer recurrence risk score for each patient. This score empowers physicians to make informed treatment decisions, potentially paving the way for:

• Reduced reliance on unnecessary chemotherapy: By accurately identifying patients with a low risk of recurrence, the AI model can help avoid unnecessary exposure to the harmful side effects of chemotherapy. This not only improves patient quality of life but also reduces the financial burden on healthcare systems.
• Targeted therapy for high-risk patients: For those patients predicted to be at high risk of recurrence, the model can guide physicians towards more aggressive treatment options, potentially improving their chances of successful long-term outcomes.

Beyond the Numbers

The impact of this AI-driven approach extends far beyond mere cost savings and treatment optimization. It marks a significant step towards personalized medicine, where each patient receives a tailored treatment plan based on their unique biological and clinical profile. This shift empowers both patients and physicians, fostering a more collaborative and informed treatment journey.

A Collaborative Journey

The Aiforia-Mayo Clinic partnership extends far beyond the development of this single model. Their collaboration began in 2020 with the implementation of Aiforia’s AI-assisted image analysis software in Mayo Clinic’s pathology research. Today, over 70 Mayo Clinic pathologists utilize Aiforia’s tools to develop their own AI models for future clinical application, and more than 30 ongoing research projects leverage Aiforia technology. This ongoing collaboration highlights a deep commitment to continuous innovation and the translation of cutting-edge AI into tangible clinical benefits.

“This is the first example of an AI model developed with the Aiforia platform, which is used to assess the risk of cancer recurrence. It is also the first clinically relevant AI model developed with a customer and commercialized by Aiforia. The licensing agreement with the Mayo Clinic enables us to market and sell this AI model for colorectal cancer recurrence risk evaluation globally, says Jukka Tapaninen, the CEO of Aiforia. “This is an example of many similar AI model co-development projects, which are ongoing with the Mayo Clinic and other partners. These will enable us to significantly enrich our product portfolio.”

What You Should Know:

– In a landmark moment for dentistry, VideaHealth, the leading dental AI platform, has secured FDA 510(k) clearance for Videa Dental Assist, a groundbreaking tool equipped with over 30 AI algorithms.

– This clearance marks a watershed moment, granting VideaHealth the distinction of being the first dental AI company to offer insights for virtually every major dental disease, including pediatric conditions.

Transforming Dental Care

Videa Dental Assist’s capabilities extend far beyond conventional AI. It boasts the world’s first FDA-cleared pediatric radiology AI, enabling dentists to confidently diagnose caries in children as young as three. Additionally, the platform features AI models for periapical radiolucencies, calculus detection, and subtle abnormalities across all ages, streamlining workflows and saving dentists valuable time.

Thousands of dentists already trust VideaAI as their go-to tool, leveraging its power to deliver superior care to millions of patients. This clearance solidifies VideaHealth’s position as the undisputed leader in dental AI, offering unparalleled insights and capabilities across the entire dental disease spectrum.

“VideaHealth’s relentless innovation continues to impress,” shared Dr. Tim Quirt, Senior Vice President of Clinical Operations at Heartland Dental. “Their commitment to empowering dentists aligns perfectly with our mission, and this expanded AI suite is a game-changer for patient care. We’re excited to implement it across our network.”

FDA Clearance Impact

• Improved accuracy and early detection: AI algorithms can identify subtle anomalies invisible to the naked eye, leading to earlier diagnoses and more effective treatment.
• Enhanced efficiency and workflow: By automating tedious tasks, VideaHealth frees up dentists’ time to focus on patient interactions and complex procedures.
• Elevated patient care: With comprehensive AI insights at their fingertips, dentists can provide more personalized and informed treatment plans, ultimately improving patient outcomes.
• Revolutionizing pediatric dentistry: Early detection of dental issues in children is crucial for preventing future complications. VideaHealth’s pediatric AI tools offer a powerful weapon in this fight.

VideaHealth’s groundbreaking achievement has the potential to reshape the landscape of dentistry, ushering in a new era of AI-powered, personalized, and efficient patient care. This is just the beginning, and the future of dental AI looks brighter than ever.

“This is one of the largest, most impactful FDA clearances in the history of healthcare,” stated Florian Hillen, CEO of VideaHealth. “It elevates patient care for millions and further cements VideaHealth as the premier AI partner for dentists worldwide.”

What You Should Know:

– Eli Lilly and Company (NYSE: LLY) announced today the launch of LillyDirect™, a comprehensive digital healthcare platform designed to empower patients living with obesity, migraine, and diabetes in the U.S. This innovative initiative aims to simplify chronic disease management by offering convenient resources, personalized support, and direct home delivery of select Lilly medications.

Key Features of LillyDirect

LillyDirect Pharmacy Solutions: This digital pharmacy platform simplifies access to select Lilly medications through third-party online fulfillment services. Patients can enjoy the convenience of home delivery and automatic application of Lilly’s affordability solutions and savings cards, if applicable.

Educational Resources: LillyDirect provides valuable information and support tailored to each disease state, empowering patients to make informed decisions and manage their health effectively.

Telehealth Access: Patients can connect with independent telehealth providers, complementing their existing care team or offering an alternative for specific needs.

Healthcare Provider Search Tool: For those seeking in-person care, LillyDirect offers an independent search tool to locate healthcare professionals near them.

“Digital solutions have become increasingly important in our daily lives, and healthcare is no exception,” remarked Frank Cunningham, group vice president, global value and access at Lilly. “LillyDirect is designed to provide patients with a seamless and convenient experience for managing their health and accessing their medications, allowing them to focus on living their lives.”